GlassScriptPhysician profile
Maulik D Shah
NPI 1003336751
$1,717.75
in general payments reported to CMS, 2019-2025
13 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $261 · 2024: $698 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.55 | 2023-2025 | Skyrizi, Linzess, Viberzi |
| Phathom Pharmaceuticals, INC. | $385.69 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $206.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $125.64 | 2025 | |
| Janssen Biotech, INC. | $93.93 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $74.32 | 2025 | Sucraid |
| Lilly USA, LLC | $55.33 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.78 | 2025 | Xifaxan |
| Braintree Laboratories, INC. | $48.58 | 2024-2025 | Suflave, Sutab |
| Capsovision, INC. | $37.25 | 2024 | Capsocam Plus |
| Novo Nordisk INC | $19.94 | 2025 | Wegovy |
| Ardelyx, INC. | $18.04 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $17.87 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maulik Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.